FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387420597> ?p ?o ?g. }

• W4387420597 endingPage "671" @default.
• W4387420597 startingPage "667" @default.
• W4387420597 abstract "Objective: To evaluate the efficacy and safety of bendamustine combined with pomalidomide and dexamethasone (BPD regimen) in the treatment of relapsed multiple myeloma (MM) with extramedullary disease. Methods: This open, single-arm, multicenter prospective cohort study included 30 relapsed MM patients with extramedullary disease diagnosed in seven hospitals including Qingdao Municipal Hospital. The patients were treated with BPD regimen from February 2021 to November 2022. This study analyzed the efficacy and adverse reactions of the BPD regimen. Results: The median age of the 30 patients was 62 (47-72) years, of which 18 (60% ) had first-time recurrence. The overall response rate (ORR) of the 18 patients with first-time recurrence was 100%, of which three (16.7% ) achieved complete remission, 10 (55.5% ) achieved very good partial remission (VGPR), and five (27.8% ) achieved partial remission (PR). The ORR of 12 patients with recurrence after second-line or above treatment was 50%, including zero patients with ≥VGPR and six patients (50% ) with PR. Three cases (25% ) had stable disease, and three cases (25% ) had disease progression. The one-year progression free survival rate of all patients was 65.2% (95% CI 37.2% -83.1% ), and the 1-year overall survival rate was 90.0% (95% CI 76.2% -95.4% ). The common grade 3-4 hematology adverse reactions included two cases (6.7% ) of neutropenia and one case (3.3% ) of thrombocytopenia. The overall adverse reactions are controllable. Conclusions: The BPD regimen has good efficacy and tolerance in relapsed MM patients with extramedullary disease.目的： 评估苯达莫司汀联合泊马度胺、地塞米松（BPD方案）治疗伴髓外病变的复发多发性骨髓瘤（MM）的疗效和安全性。 方法： 本项开放、单臂、多中心前瞻性研究纳入2021年2月至2022年11月在青岛市市立医院等7所医院诊断并接受BPD方案治疗的30例伴髓外病变的复发MM患者，分析其疗效及不良反应。 结果： 30例患者中位年龄62（47~72）岁，其中18例（60.0%）为首次复发，首次复发的18例患者的总体反应率（ORR）为100%，其中完全缓解3例（16.7%），非常好的部分缓解（VGPR）10例（55.5%），部分缓解（PR）5例（27.8%）。12例二线以上治疗后复发患者的ORR为50%，其中≥VGPR 0例，PR 6例（50%），疾病稳定3例（25%），疾病进展3例（25%）。所有患者的1年无进展生存率为65.2%（95%CI 37.2%~83.1%），1年总生存率为90.0%（95%CI 76.2%~95.4%）。常见的3~4级血液学不良反应包括中性粒细胞减少2例（6.7%），血小板减少1例（3.3%），总体不良反应可控。 结论： BPD方案在伴髓外病变的复发MM患者中具有良好的疗效和耐受性。." @default.
• W4387420597 created "2023-10-08" @default.
• W4387420597 creator A5000867726 @default.
• W4387420597 creator A5013895692 @default.
• W4387420597 creator A5014903854 @default.
• W4387420597 creator A5018793696 @default.
• W4387420597 creator A5019715955 @default.
• W4387420597 creator A5041324986 @default.
• W4387420597 creator A5045483608 @default.
• W4387420597 creator A5048442481 @default.
• W4387420597 creator A5069667571 @default.
• W4387420597 creator A5090567341 @default.
• W4387420597 date "2023-08-14" @default.
• W4387420597 modified "2023-10-10" @default.
• W4387420597 title "[Bendamustine combined with pomalidomide and dexamethasone in relapsed multiple myeloma with extramedullary disease: a multicenter study]." @default.
• W4387420597 cites W1988998251 @default.
• W4387420597 cites W2057660602 @default.
• W4387420597 cites W2066700805 @default.
• W4387420597 cites W2066713758 @default.
• W4387420597 cites W2125477622 @default.
• W4387420597 cites W2136541422 @default.
• W4387420597 cites W2326706351 @default.
• W4387420597 cites W2486629951 @default.
• W4387420597 cites W2564461246 @default.
• W4387420597 cites W2790464636 @default.
• W4387420597 cites W2886312146 @default.
• W4387420597 cites W2952686607 @default.
• W4387420597 cites W3203424381 @default.
• W4387420597 cites W4225280449 @default.
• W4387420597 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2023.08.009" @default.
• W4387420597 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37803841" @default.
• W4387420597 hasPublicationYear "2023" @default.
• W4387420597 type Work @default.
• W4387420597 citedByCount "0" @default.
• W4387420597 crossrefType "journal-article" @default.
• W4387420597 hasAuthorship W4387420597A5000867726 @default.
• W4387420597 hasAuthorship W4387420597A5013895692 @default.
• W4387420597 hasAuthorship W4387420597A5014903854 @default.
• W4387420597 hasAuthorship W4387420597A5018793696 @default.
• W4387420597 hasAuthorship W4387420597A5019715955 @default.
• W4387420597 hasAuthorship W4387420597A5041324986 @default.
• W4387420597 hasAuthorship W4387420597A5045483608 @default.
• W4387420597 hasAuthorship W4387420597A5048442481 @default.
• W4387420597 hasAuthorship W4387420597A5069667571 @default.
• W4387420597 hasAuthorship W4387420597A5090567341 @default.
• W4387420597 hasConcept C126322002 @default.
• W4387420597 hasConcept C141071460 @default.
• W4387420597 hasConcept C197934379 @default.
• W4387420597 hasConcept C2776364478 @default.
• W4387420597 hasConcept C2776694085 @default.
• W4387420597 hasConcept C2777063308 @default.
• W4387420597 hasConcept C2777478702 @default.
• W4387420597 hasConcept C2778524551 @default.
• W4387420597 hasConcept C2779338263 @default.
• W4387420597 hasConcept C2780401358 @default.
• W4387420597 hasConcept C2780653079 @default.
• W4387420597 hasConcept C2781413609 @default.
• W4387420597 hasConcept C2781442060 @default.
• W4387420597 hasConcept C71924100 @default.
• W4387420597 hasConcept C90924648 @default.
• W4387420597 hasConceptScore W4387420597C126322002 @default.
• W4387420597 hasConceptScore W4387420597C141071460 @default.
• W4387420597 hasConceptScore W4387420597C197934379 @default.
• W4387420597 hasConceptScore W4387420597C2776364478 @default.
• W4387420597 hasConceptScore W4387420597C2776694085 @default.
• W4387420597 hasConceptScore W4387420597C2777063308 @default.
• W4387420597 hasConceptScore W4387420597C2777478702 @default.
• W4387420597 hasConceptScore W4387420597C2778524551 @default.
• W4387420597 hasConceptScore W4387420597C2779338263 @default.
• W4387420597 hasConceptScore W4387420597C2780401358 @default.
• W4387420597 hasConceptScore W4387420597C2780653079 @default.
• W4387420597 hasConceptScore W4387420597C2781413609 @default.
• W4387420597 hasConceptScore W4387420597C2781442060 @default.
• W4387420597 hasConceptScore W4387420597C71924100 @default.
• W4387420597 hasConceptScore W4387420597C90924648 @default.
• W4387420597 hasIssue "8" @default.
• W4387420597 hasLocation W43874205971 @default.
• W4387420597 hasOpenAccess W4387420597 @default.
• W4387420597 hasPrimaryLocation W43874205971 @default.
• W4387420597 hasRelatedWork W1966942554 @default.
• W4387420597 hasRelatedWork W2017521062 @default.
• W4387420597 hasRelatedWork W2055453275 @default.
• W4387420597 hasRelatedWork W2104844017 @default.
• W4387420597 hasRelatedWork W2146775426 @default.
• W4387420597 hasRelatedWork W2192430028 @default.
• W4387420597 hasRelatedWork W2335826388 @default.
• W4387420597 hasRelatedWork W2593038620 @default.
• W4387420597 hasRelatedWork W2886312146 @default.
• W4387420597 hasRelatedWork W3028759878 @default.
• W4387420597 hasVolume "44" @default.
• W4387420597 isParatext "false" @default.
• W4387420597 isRetracted "false" @default.
• W4387420597 workType "article" @default.